

**IN THE CLAIMS**

1. (previously presented) A method of preparing a dry powder inhalation composition comprising the steps of:

(a) mixing an inert particulate carrier with a first portion of a first particulate inhalant medicament to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier;

(b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and

(c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier.

2. (previously presented) A method according to claim 1, wherein the first portion of the first particulate inhalant medicament is less than half weight by weight of the total amount of the first particulate inhalant medicament in the dry powder inhalation composition.

3. (previously presented) A method according to claim 1, wherein the first portion of first particulate inhalant

medicament is less than 2% weight by weight of the total amount of the particulate carrier.

4. (canceled).

5. (previously presented) A method according to claim 1, wherein the particulate carrier is lactose.

6. (previously presented) A method according to claim 1, wherein the first particulate inhalant medicament is an anti-inflammatory steroid or a pharmaceutically acceptable salt, solvate or salt solvate thereof.

7. (previously presented) A method according to claim 1, 5 or 6, wherein the first particulate inhalant medicament is budesonide or a pharmaceutically acceptable salt, solvate or salt solvate thereof.

8. (previously presented) A method according to claim 1 or 5, wherein the second particulate inhalant medicament is a bronchodilator or a pharmaceutically acceptable salt, solvate or salt solvate thereof.

9. (previously presented) A method according to claim 1, 5 or 6, wherein the second particulate inhalant medicament is formoterol or a pharmaceutically acceptable salt, solvate or salt solvate thereof.

10. (previously presented) A method according to claim 1, wherein the ratio of the first particulate inhalant medicament to the second particulate inhalant medicament by weight is from 5:1 to 100:1.

11. (previously presented) A dry powder inhalation composition prepared by a process comprising the steps of:

- (a) mixing an inert particulate carrier with a first portion of a first particulate inhalant medicament to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier;
- (b) mixing said first mixture with a second particulate inhalant medicament to form a second mixture; and
- (c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier, and wherein the dry powder inhalation composition consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

12. (previously presented) A dry powder inhalation composition according to claim 11, wherein the first particulate inhalant medicament is budesonide or a pharmaceutically acceptable salt, solvate or salt solvate thereof.

13. (previously presented) A dry powder inhalation composition according to claim 11, wherein the second particulate inhalant medicament is formoterol fumarate dihydrate.

14. (previously presented) A MDPI comprising a composition according to any one of claims 11-13.

15. (previously presented) A method for the administration of a particulate medicament, comprising inhalation from a multidose dry powder inhaler of a composition of any one of claims 11-13.

16. (previously presented) The method of claim 1, wherein the dry powder inhalation composition of step (c) consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

17. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 50 to about 60  $\mu\text{m}$ .

18. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 60 to about 90  $\mu\text{m}$ .

19. (previously presented) A dry powder inhalation composition according to claim 11, wherein said particulate carrier has a VMD of from about 90 to about 150  $\mu\text{m}$ .

20. (new) A method of preparing a dry powder inhalation composition comprising the steps of:

(a) mixing an inert particulate carrier with a first portion of a first particulate inhalant medicament comprising an anti-inflammatory steroid to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to

create a monolayer of the first particulate inhalant medicament on the particulate carrier;

(b) mixing said first mixture with a second particulate inhalant medicament comprising a bronchodilator to form a second mixture; and

(c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier.

21. (new) A method according to claim 20, wherein the first portion of the first particulate inhalant medicament is less than half weight by weight of the total amount of the first particulate inhalant medicament in the dry powder inhalation composition.

22. (new) A method according to claim 20, wherein said particulate carrier comprises lactose.

23. (new) A method according to claim 20, wherein said anti-inflammatory steroid comprises budesonide.

24. (new) A method according to claim 20, wherein said bronchodilator comprises formoterol.

25. (new) A method according to claim 20, wherein the ratio of said first particulate inhalant medicament to said second particulate inhalant medicament by weight is from 5:1 to 100:1.

26. (new) A dry powder inhalation composition prepared by a process comprising the steps of:

- (a) mixing an inert particulate carrier with a first portion of a first particulate inhalant medicament comprising an anti-inflammatory steroid to form a first mixture, wherein said particulate carrier has a volume median diameter (VMD) of from about 50 to about 250  $\mu\text{m}$ , wherein the first portion of the first particulate inhalant medicament is sufficient to create a monolayer of the first particulate inhalant medicament on the particulate carrier;
- (b) mixing said first mixture with a second particulate inhalant medicament comprising a bronchodilator to form a second mixture; and
- (c) mixing said second mixture with a second portion of the first particulate inhalant medicament to form a dry powder inhalation composition,

wherein, in the dry powder inhalation composition from step (c), the ratio by weight of the second particulate inhalant medicament to the carrier is less than the ratio by weight of the first particulate inhalant medicament to the carrier, and wherein the dry powder inhalation composition consists of said particulate carrier, said first particulate inhalant medicament and said second particulate inhalant medicament.

27. (new) A dry powder inhalation composition according to claim 26, wherein said anti-inflammatory steroid comprises budesonide.

28. (new) A dry powder inhalation composition according to claim 26, wherein said bronchodilator comprises formoterol.

29. (new) A dry powder inhalation composition according to claim 28, wherein said formoterol comprises formoterol fumarate dihydrate.

30. (new) A dry powder inhalation composition according to claim 26, wherein said particulate carrier has a VMD of from about 50 to about 60  $\mu\text{m}$ .

31. (new) A dry powder inhalation composition according to claim 26, wherein said particulate carrier has a VMD of from about 60 to about 90  $\mu\text{m}$ .

32. (new) A dry powder inhalation composition according to claim 26, wherein said particulate carrier has a VMD of from about 90 to about 150  $\mu\text{m}$ .